Form 4: BeOne Medicines COO Sells Shares Under 10b5-1 Plan

BeOne Medicines Ltd.'s President and COO, Wu Xiaobin, reported the sale of American Depositary Shares totaling 15,999 units over two days in November 2025.

Summary

• Wu Xiaobin, President and COO of BeOne Medicines Ltd., sold a total of 15,999 American Depositary Shares (ADS) on November 12 and 13, 2025.
• The sales were executed at weighted average prices ranging from $350.441 to $381.0497 per ADS.
• These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these transactions, Wu Xiaobin directly holds 0 American Depositary Shares and 1,020,861 Ordinary Shares, which includes 650 ordinary shares acquired via the Company's Fourth Amended and Restated 2018 Employee Share Purchase Plan.
• An additional 4,000 American Depositary Shares are indirectly beneficially owned by Wu Xiaobin's wife.
• Each American Depositary Share represents 13 Ordinary Shares.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to significant insider selling by a key executive, even though it was conducted under a Rule 10b5-1 plan. While planned sales are less alarming than unplanned ones, they still represent a reduction in direct ownership by a person with deep company knowledge.

Negatives

• President and COO Wu Xiaobin sold a significant number of American Depositary Shares (15,999 units) over two days.
• The direct beneficial ownership of American Depositary Shares by the reporting person is now 0.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects or that the stock price is currently high, potentially leading to negative investor sentiment.

Future Outlook

NA

Industry Context

This Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. The sale of shares by a high-ranking executive like a President and COO can sometimes be viewed by the market as a signal, though the presence of a Rule 10b5-1 plan suggests the transaction was pre-scheduled and not necessarily based on new, non-public information.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a potential signal regarding the company's valuation or future prospects, potentially leading to decreased investor confidence.
• The reduction of direct beneficial ownership by a key executive could raise questions among investors about management's long-term commitment or belief in the stock's upside.

Key Dates

Recommendation

While the President and COO sold a substantial number of shares, the transactions were executed under a pre-arranged Rule 10b5-1 plan, which mitigates the immediate negative signal compared to unplanned sales. However, the significant reduction in direct beneficial ownership by a key executive warrants caution. Investors should hold their positions and monitor future company performance and additional insider activity for clearer directional signals, as this event alone does not provide a strong enough catalyst for a 'buy' or 'sell' recommendation.

Keywords

BeOne Medicines, ONC, Insider Trading, Form 4, Share Sale, Executive Compensation, Wu Xiaobin, American Depositary Shares, ADS, Rule 10b5-1